Summary of Product Characteristics (SmPC) - Vitamin B Compound Strong tablets
1 NAME OF THE MEDICINAL PRODUCT
Vitamin B Compound Strong Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains
20mg Nicotinamide,
2mg Pyridoxine Hydrochloride,
2mg Riboflavine and
4.85mg Thiamine Mononitrate.
Excipient with known effect: lactose.
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Film-coated tablet (Tablets)
Brown coloured, circular, film coated tablets with debossed ‘BP’ on one side and ‘2’ on other side.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the treatment of clinical and sub-clinical vitamin B deficiency states (manifestations of which include glossitis, stomatitis, cheilosis, the heart manifestations of beriberi, the skin manifestations of pellagra, corneal vascularisation and polyneuritis).
4.2 Posology and method of administration
Posology
Adults (including elderly) and children over 3 years: One to two tablets three times daily.
Paediatric population
Should not be used in children under 3 years.
Method of administration
For oral administration.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Pyridoxine may increase the peripheral metabolism of levodopa, reducing therapeutic efficacy of the latter drug. Therefore, patients with Parkinson's disease who are receiving treatment with plain levodopa should not take vitamin B6 in doses which greatly exceed the daily requirement. This does not apply when levodopa is combined with a peripheral decarboxylase inhibitor.
4.6 Fertility, Pregnancy and lactation
Pregnancy:
| There is limited amount of data from the use of the product in pregnant | ||||
| women. Animal studies are insufficient with respect to reproductive toxicity. | ||||
| The use of the product is individualized based on condition and requirements | ||||
| in pregnant women and can be used in pregnant women if use is necessary to | ||||
| correct deficiencies and if benefits overweighs risks. | ||||
| Caution should be exercised when prescribing to pregnant women | ||||
| Breast-feeding: | ||||
| The ingredients of Vitamin B compound tablets are excreted via human milk. | |
| No harm to suckling infant is expected if used in recommended doses. High | |
| concentrations of vitamin B6 can inhibit the production of breast milk. | |
| However, the use should be individualized based on nutritional status of the | |
| lactating women and infant. The diet and use of any additional B vitamin | |
| supplements in both mother and infant should be reassessed so that neither | |
| excess nor lesser B vitamins available to lactating women and infant. | |
| In high doses, pyridoxine may interfere with prolactin release and should only | |
| be used with caution in nursing mothers. | |
Fertility: No relevant data is available
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
| Vitamin B Compound Strong tablets are unlikely to cause any side effects, as any | |
| excess vitamin B is naturally excreted from the body. | |
| Seek medical attention right away if any of these SEVERE side effects like severe | |
| allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; | |
| swelling of the mouth, face, lips, or tongue); feeling of swelling of the entire body; | |
| numbness or tingling of the skin occur while taking Vitamin B Compound Strong) | |
| Reporting of suspected adverse reactions | |
| Reporting suspected adverse reactions after authorisation of the medicinal product is | |
| important. It allows continued monitoring of the benefit/risk balance of the medicinal | |
| product. Healthcare professionals are asked to report any suspected adverse reactions | |
| via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. |
4.9 Overdose
| Excess vitamin B is readily excreted, therefore no serious problems are anticipated | |
| for the administration of vitamin B in this form. | |
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Nicotinamide is a vitamin
Pyridoxine hydrochloride is a vitamin (B6)
Riboflavine is a vitamin (B2)
Thiamine mononitrate is a vitamin (B1)
The ATC code of Vitamin B complex is A11EA. The vitamin B-complex comprises a group of water-soluble factors more or less closely associated in their natural occurrence. It is known that nearly every vitamin of the B-complex forms part of a co-enzyme essential for the metabolism of protein, carbohydrate or fatty acid.
5.2 Pharmacokinetic properties
Nicotinamide is readily absorbed from the GI tract following oral administration and is widely distributed in the body tissues. Small amounts of nicotinamide are excreted unchanged in urine following therapeutic doses, however, the amount excreted unchanged is increased with larger doses. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. Riboflavine is absorbed from the GI tract and in the circulation is bound to plasma proteins. Although widely distributed, little is stored in the body, and amounts in excess of requirements are excreted in the urine. Thiamine is absorbed from the GI tract and is widely distributed to most body tissues. It is not stored to any appreciable extent in the body and amounts in excess of requirements are excreted in the urine as unchanged thiamine or metabolites.
5.3 Preclinical safety data
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use and development
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Tablet core contains:
Lactose monohydrate
Microcrystalline cellulose Starch Pregelatinized,
Colloidal silicon dioxide Magnesium stearate
Film coat contains:
Hypromellose E464
Hydroxy Propyl Cellulose Black Iron Oxide E172
Iron Oxide Red E172
Macrogol E1521
Titanium Dioxide E171
Medium Chain Triglycerides
6.2 Incompatibilities
None Known.
6.3 Shelf life
24 Months
6.4 Special precautions for storage
Store below 25°C in original package in order to protect from moisture.
6.5 Nature and contents of container
28 film-coated tablets in clear PVC/PVdC-A1u Blister pack.
6.6 Special precautions for disposal
None.
7 MARKETING AUTHORISATION HOLDER
Blue Bio Pharma (UK) Limited
167-169 Great Portland Street,
Fifth Floor, London W1W 5PF
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 53594/0004
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
04/02/2025
10 DATE OF REVISION OF THE TEXT
04/02/2025